Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
MDI-2517 by MDI Therapeutics for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
MDI-2517 is under clinical development by MDI Therapeutics and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung...
Data Insights
MDI-2517 by MDI Therapeutics for Systemic Sclerosis (Scleroderma): Likelihood of Approval
MDI-2517 is under clinical development by MDI Therapeutics and currently in Phase I for Systemic Sclerosis (Scleroderma). According to GlobalData,...